Abstract:Cancer is a perilous life-threatening disease, and attempts are constantly made to create multinuclear transition metal complexes that could lead to potential anticancer medications and administration procedures. Hence, this work aims to design, synthesize, characterize, and assess the anticancer efficacy of ruthenium p-cymene complexes incorporating N, N'- bis(4-substituted benzoyl)hydrazine ligands. The formation of the new complexes (Ru2H1-Ru2H3) has been thoroughly established by elemental analysis, FT-IR, UV-vis, NMR, and HR-MS spectral techniques. The solid-state molecular structures of the complexes Ru2H1 and Ru2H3 have been determined using the SC-XRD study, which confirms the N, O, and Cl-legged piano stool pseudo-octahedral geometry on each ruthenium(II) ion. The stability of these complexes in the solution state and their lipophilicity profile have been determined. Further, the titled complexes were tested for their in vitro anticancer activity against the cancerous H460 (lung cancer cells), SkBr3 (breast cancer cells), HepG2 (liver cancer cells), and Hela (cervical cancer cells) along with non-cancerous (HEK-293) cells. The IC50 results revealed that complex Ru2H3 exhibits potent activity against the proliferation of all four cancer cells and outscored the effect of standard metallodrug cisplatin. This may be attributed to the presence of a couple of lipophilic electron-donating methoxy groups in the ligand scaffold and also the ruthenium(II) p-cymene motifs. Advantageously, all the complexes (Ru2H1-Ru2H3) displayed cytotoxic specificity only towards the cancerous cell by leaving the off-target non-cancerous cells undamaged. Acridine orange/ethidium bromide (AO/EB) staining, Hoechst 33342, Mitochondrial Membrane Potential (MMP), and Reactive Oxygen Species (ROS) staining assays were used to investigate the apoptotic pathway and ROS levels in mitochondria. The results of Western blot analysis confirmed that complexes triggered apoptosis through intrinsic mitochondrial pathway by upregulating Bax and downregulating Bcl-2 proteins. Finally, the extent of apoptosis triggered by complex (Ru2H3) was quantified with the aid of flow cytometry using the Annexin V-FITC/propidium iodide (PI) double-staining technique.

Anticancer Activity of Bifunctional Organometallic Ru(II) Arene Complexes Containing a 7-Hydroxycoumarin Group

Bifunctional Ruthenium(ii) Polypyridyl Complexes of Curcumin As Potential Anticancer Agents

Exploring the Cytotoxicity of Dinuclear Ru(II) p-cymene Complexes Appended N,N'-Bis(4-substituted benzoyl)hydrazines: Insights into the Mechanism of Apoptotic Cell Death

Antitumor Effect of Organometallic Half-Sandwich Ru(II)-Arene Complexes Bearing a Glutathione <i>S</i>-Transferase Inhibitor

Synthesis, characterization, and anticancer activity of ruthenium(II)-β-carboline complex.

Organometallic Ru(Ⅱ) Complexes As Anticancer Agents

Bioactive ruthenium(II)-arene complexes containing modified 18β-glycyrrhetinic acid ligands.

Ruthenium-Arene-β-Carboline Complexes As Potent Inhibitors of Cyclin-Dependent Kinase 1: Synthesis, Characterization and Anticancer Mechanism Studies.

Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands

Study on the Multimodal Anticancer Mechanism of Ru(II)/Ir(III) Complexes Bearing a Poly(ADP-ribose) Polymerase 1 Inhibitor.

Cytotoxicity in vitro, cellular uptake, localization and apoptotic mechanism studies induced by ruthenium(II) complex

Design, synthesis and anticancer evaluation of novel half-sandwich Ru(II) complexes bearing pyrazalone moiety: Apoptosis inducers based on mitochondrial dysfunction and G0/G1 arrest

Dinuclear arene ruthenium(II) arylthiourea complexes: Synthesis, structure, cancer cell growth inhibition and apoptosis induction studies

Cyclometalated Ru(II)-NHC Complexes with Phenanthroline Ligand Induce Apoptosis Mediated by Mitochondria and Endoplasmic Reticulum Stress in Cancer Cells

Synthesis, Crystal and Electronic Structure, Anticancer Activity of Ruthenium(Ii) Arene Complexes with Thiosemicarbazones

Synthesis, characterization, and anticancer activity of Ru( p -cymene) complexes bearing pyrazolyl–pyridine type ligands

Ligand-Based Neutral Ruthenium(Ii) Arene Complex: Selective Anticancer Action

Hypoxia-Targeting Organometallic Ru(II)-Arene Complexes with Enhanced Anticancer Activity in Hypoxic Cancer Cells.

Novel Dinuclear Arene Ruthenium(ii) Complexes: Synthesis, Structure, Anticancer Activity and Interaction with DNA

Anti-metastasis and anti-proliferation effect of mitochondria-accumulating ruthenium(II) complexes via redox homeostasis disturbance and energy depletion

Synthesis, characterization, and antitumor activity of mononuclear and dinuclear ruthenium complexes